Home Crystal structure of 4-ethyl-3-phenylisoquinolin-1(2H)-one, C17H15NO
Article Open Access

Crystal structure of 4-ethyl-3-phenylisoquinolin-1(2H)-one, C17H15NO

  • Hui-Mei Lin , Jia-Yin Peng , Ting-Guang Zou , Wan-Yi Xu , Yi-Wen Tao ORCID logo EMAIL logo and Bao-Long Lai EMAIL logo
Published/Copyright: October 12, 2020

Abstract

C17H15NO, monoclinic, C2/c (no. 15), a = 19.197(2) Å, b = 8.0719(8) Å, c = 16.6511(18) Å, α = 90°, β = 100.171(10)°, γ = 90°,V = 2539.6(5) Å3, Z = 8, Rgt(F) = 0.0416, wRref(F2) = 0.1107, T = 100(1) K.

CCDC no.: 2020262

The molecular structure is shown in the Figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colorless block
Size:0.12 × 0.11 × 0.10 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:0.00 mm−1
Diffractometer, scan mode:SuperNova, ω
θmax, completeness:29.4°, >99%
N(hkl)measured, N(hkl)unique, Rint:6380, 2244, 0.025
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 1973
N(param)refined:174
Programs:CrysAlisPRO [1], SHELX [2], Olex2 [3]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.49210 (5)0.86764 (13)0.41927 (6)0.0259 (3)
N10.42616 (6)0.84912 (15)0.51924 (7)0.0209 (3)
C10.39462 (7)0.52179 (18)0.48496 (9)0.0217 (3)
H10.435620.9512380.5312480.025*
C20.38299 (8)0.35252 (19)0.46581 (10)0.0264 (4)
H20.3596080.2870550.4985750.032*
C30.40561 (8)0.28260 (19)0.39954 (10)0.0289 (4)
H30.3969690.1709450.3881110.035*
C40.44125 (8)0.37619 (19)0.34927 (10)0.0277 (4)
H40.4549930.3283750.3037070.033*
C50.45585 (7)0.53972 (19)0.36769 (9)0.0240 (4)
H50.4809840.6020270.3354780.029*
C60.43305 (7)0.61337 (18)0.43489 (9)0.0207 (3)
C70.45306 (7)0.78422 (18)0.45575 (8)0.0207 (3)
C80.38463 (7)0.76458 (18)0.56651 (8)0.0197 (3)
C90.36984 (7)0.60136 (18)0.55301 (9)0.0213 (3)
C100.28846 (8)0.88532 (19)0.63265 (10)0.0276 (4)
H100.2554210.8250610.5965890.033*
C110.26581 (9)0.9902 (2)0.68890 (11)0.0340 (4)
H110.2177871.0002150.6903660.041*
C120.31462 (9)1.0797 (2)0.74261 (10)0.0343 (4)
H120.2994671.1498930.7803290.041*
C130.38618 (9)1.06506 (19)0.74047 (9)0.0307 (4)
H130.4190111.125090.7768910.037*
C140.40882 (8)0.96117 (18)0.68415 (9)0.0245 (4)
H140.4568780.9525150.6826260.029*
C150.36025 (7)0.86946 (17)0.62972 (9)0.0215 (3)
C160.33272 (8)0.50005 (19)0.60948 (10)0.0271 (4)
H16A0.3331710.5624450.659360.032*
H16B0.3596040.3993180.6238180.032*
C170.25650 (8)0.4528 (2)0.57485 (11)0.0333 (4)
H17A0.2545850.4003580.5227540.050*
H17B0.2276070.5506040.5684670.050*
H17C0.2392690.3775810.6115050.050*

Source of material

Strain Fusarium sp. was obtained from the stem of mangrove Sonneratia apetala collected from Dongzhai Harbor, Hainan province, China, and identified by 18S RNA gene sequence [4]. The specimen was stored at Guangzhou Medical University, Guangzhou, P. R. China. The stored strain was recovered from solid culture medium and transferred aseptically to a 250 mL Erlenmeyer flask containing 100 mL liquid medium (glucose 10 g/L, peptone 2 g/L, yeast extract 1 g/L, sea salt 2 g/L). The fungus was cultured at 28 °C for 30 days [5]. The culture was filtered through cheesecloth. The mycelium was air-dried, extracted with methanol, and then dried with rotary evaporator. The extract was further fractionated by silica gel chromatography using a stepwise gradient solvent system according to the increasing polarity starting from 100% petroleum to 100% methanol. The title compound was isolated and purified from 75% petroleum/25% ethyl acetate fraction through silica gel column chromatography. Colorless block crystals were obtained from slow evaporation of the chloroform solution in the NMR tube at room temperature.

Experimental details

All hydrogen atoms were placed in calculated positions and refined using a riding model with the relative isotropic parameters. Uiso values of hydrogen atoms were set to 1.2 Ueq of the parent atoms.

Comment

The title crystal structure was elucidated by MS and NMR data [6], [7], [8], [9], [10], [11], and confirmed by X-ray crystallography (see the figure). The study on the biological activities of this compound has never been reported so far. Geometric parameters are all in the expected ranges [12].


Corresponding author: Yi-Wen Tao, Key Laboratory of Molecular Target & Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong511436, P. R. China; and Bao-Long Lai, Department of Pharmacy, The 7th Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong518107, P. R. China, (Y.-W. Tao), (B.-L. Lai)
Jia-Yin Peng: Co-first author.

Funding source: Guangdong Natural Science Foundation of China

Award Identifier / Grant number: 2018A0303130201

Funding source: Guangzhou Education Bureau Yangcheng Scholars Project

Award Identifier / Grant number: 202032774

Funding source: Scientific Research Foundation of Traditional Chinese Medicine of Health and Family Planning Bureau from Guangming District

Award Identifier / Grant number: GM2019020026

Funding source: National Students Training Programs for innovation and Entrepreneurship

Award Identifier / Grant number: 202010570028

Funding source: Special Funds for Undergraduates Scientific and Technological Innovation Training Programs in Guangdong

Award Identifier / Grant number: pdjh2020b0487

Award Identifier / Grant number: S201910570075

Award Identifier / Grant number: S201910570069

Award Identifier / Grant number: 201810570078

Funding source: Undergraduate Training Programs for Innovation and Entrepreneurship in GZHMU

Award Identifier / Grant number: 2019A076

Award Identifier / Grant number: 2018A107

Award Identifier / Grant number: 2018A103

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

Research funding

This work was supported by Guangdong Natural Science Foundation of China (2018A0303130201), Guangzhou Education Bureau Yangcheng Scholars Project (202032774), Scientific Research Foundation of Traditional Chinese Medicine of Health and Family Planning Bureau from Guangming District (GM2019020026), National Students Training Programs for innovation and Entrepreneurship (202010570028), Special Funds for Undergraduates Scientific and Technological Innovation Training Programs in Guangdong (pdjh2020b0487, S201910570075, S201910570069, 201810570078), and Undergraduate Training Programs for Innovation and Entrepreneurship in GZHMU (2019A076, 2018A107, 2018A103).

References

1. Agilent Technologies. CrysAlisPRO Software System, Version 1.171.37.35; Agilent Technologies UK Ltd: Oxford, UK, 2011.Search in Google Scholar

2. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. 2008, A64, 112–122; https://doi.org/10.1107/s0108767307043930.Search in Google Scholar

3. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

4. Tao, Y. W., Lin, Y. C., She, Z. G., Lin, M. T., Chen, P. X., Zhang, J. Y. Anticancer activity and mechanism investigation of beauvericin isolated from secondary metabolites of the mangrove endophytic fungi. Anticancer Agents Med. Chem. 2015, 15, 258–266; https://doi.org/10.2174/1871520614666140825112255.Search in Google Scholar

5. Zhang, J. Y., Lai, Z. Z., Wen, J. H., Ling, H. P., Lin, M. T., Tang, S. L., Liu, Y., Tao, Y. W. Apicidin inhibited proliferation and invasion and induced apoptosis via mitochondrial pathway in non-small cell lung cancer GLC-82 cells. Anticancer Agents Med. Chem. 2017, 17, 1374–1382; https://doi.org/10.2174/1871520617666170419120044.Search in Google Scholar

6. Yang, J., Wu, L. X., Xu, H. Y., Gao, H., Zhou, Z., Yi, W. Redox-neutral [4 + 2] annulation of N-methoxybenzamides with alkynes enabled by an osmium(II)/HOAc catalytic system. Org. Lett. 2019, 21, 9904–9908; https://doi.org/10.1021/acs.orglett.9b03827.Search in Google Scholar

7. Guo, S. H., Sun, L. C., Liu, Y. F., Ma, N. N., Zhang, X. Y., Fan, X. S. Rh(III)-catalyzed oxidative spirocyclization of isoquinolones with α-diazo-1,3-indandiones. Org. Lett. 2019, 21, 4082–4086; https://doi.org/10.1021/acs.orglett.9b01263.Search in Google Scholar

8. Yu, X. L., Chen, K. H., Guo, S., Shi, P. F., Song, C., Zhu, J. Direct access to cobalt acycles via C–H activation: N-chloroamide-enabled room-temperature synthesis of heterocycles. Org. Lett. 2017, 19, 5348–5351; https://doi.org/10.1021/acs.orglett.7b02632.Search in Google Scholar

9. Zhong, H. B., Yang, D., Wang, S. Q., Huang, J. H. Pd-catalysed synthesis of isoquinolinones and analogues via C–H and N–H bonds double activation. Chem. Commun. 2012, 48, 3236–3238; https://doi.org/10.1039/c2cc17859a.Search in Google Scholar

10. Lu, S. N., Lin, Y. F., Zhong, H. B., Zhao, K., Huang, J. H. A practical one-pot procedure for the synthesis of N–H isoquinolones. Tetrahedron Lett. 2013, 54, 2001–2005; https://doi.org/10.1016/j.tetlet.2013.02.003.Search in Google Scholar

11. Ackermann, L., Fenner, S. Ruthenium-catalyzed C–H/N–O bond functionalization: green isoquinolone syntheses in water. Org. Lett. 2011, 13, 6548–6551; https://doi.org/10.1021/ol202861k.Search in Google Scholar

12. Liu, P., Jiang, F., Huang, G., Sun, Y., Huang, L. Crystal structure of 2-butyl-6-(ethylamino)-1H-benzo[de]isoquinoline-1,3(2H)-dione, C18H20N2O2. Z. Kristallogr. NCS. 2020, 235, 147–149.10.1515/ncrs-2019-0548Search in Google Scholar

Received: 2020-08-01
Accepted: 2020-09-03
Published Online: 2020-10-12
Published in Print: 2021-01-26

© 2020 Hui-Mei Lin et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of 3-oxo-urs-12-en-28-oic acid, C30H46O3·1/6H2O
  4. The crystal structure of (3S,12R,20R,24R)-3,12-diacetyl-20,24-epoxy-dammarane-3,12,25–triol–ethyl acetate (4/1), C34H56O6⋅ 0.25(C4H8O2)
  5. A new polymorph of tetrakis(dimethylammonium) catena-poly[tetrakis(μ2-sulfato-κ2O:O′)dizinc(II)], Zn2C8H32N4O16S4
  6. Crystal structure of 10-oxysophoridine, C15H22N2O2
  7. The crystal structure of (5R,8R,9R,10R,12R,13R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)tetradecahydro-3H-cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O4
  8. Synthesis, crystal structure and optical property of 1,6-bis(p-tolylthio)pyrene, C30H22S2
  9. The crystal structure of hexakis(2-(pyridin-2-ylamino)pyridin-1-ium) decavanadate(V) dihydrate, C60H64N18O30V10
  10. Preparation and crystal structure of a cationic olefin polymerization precatalyst: (1,7-bis(2,6–dichlorophenyl)-1,7-di-aza-4-oxo-heptan-1,4,7-triyl)dimethyl zirconium(IV), C18H20Cl4N2OZr
  11. The crystal structure of fac-tricarbonyl(4,4-dimethyl-2,2-dipyridyl-κ2N,N′)- (pyrazole-κN)rhenium(I) nitrate, C18H16O3N4Re
  12. Synthesis and crystal structure of hexaaquacopper(II) 2,5-dicarboxyterephthalate, C10H16O14Cu
  13. The crystal structure of (8R,10R,12R,14R)- 12-hydroxy-16-(5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)- 4,4,8,10,14-pentamethyltetradecahydro-3H- cyclopenta[a]phenanthrene-3,6(2H)-dione, C30H48O5
  14. Structure of the mixed crystal (S)-(6-(bromo/chloro)-2-methoxy-2,6-dihydroquinolin-3-yl)(phenyl)methanol, C17H14Br0.5Cl0.5NO2
  15. The crystal structure of trans-tetraaqua-bis(4-acetylphenoxyacetato-κ1O)manganese(II), C20H26O12Mn
  16. Crystal structure of (E)-2-(4-fluoro-3-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  17. Crystal structure of DL-α-(methylaminomethyl)benzyl alcohol, C9H13NO
  18. The crystal structure of dipentaerthritol hexanitrate, C10H16N6O19
  19. Crystal structure of N,N-diphenylformamide, C13H11NO
  20. Crystal structure of (E)-2-(3,5-bis(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen- 1(2H)-one, C20H14F6O2
  21. Crystal structure of ortho-methoxy benzaldehyde, C8H8O2 – a second polymorph and deposition of 3D coordinates
  22. Crystal structure of catena-poly[diaqua-bis(μ2-2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O:O')-(2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)propanoato-κ2O,O')yttrium(III)], C51H79O11Y
  23. Crystal structure of benzylthiouronium chloride, C8H11ClN2S
  24. Synthesis and crystal structure of tert-butyl (2′R,3R,3′R,4aR,9aS)-1-acetyl-5-chloro-3″-methyl-2,5″,9′-trioxo-1″-phenyl-1″,4a′,5″,9a′-tetrahydro-1′H,3′H,9′H-dispiro[indoline-3,4′-xanthene-2′,4″-pyrazole]-3′-carboxylate, C36H32ClN3O7
  25. Crystal structure of 2-hydroxy-4-methoxy benzaldehyde, C8H8O3
  26. Crystal structure of poly[diaqua-(m3-3′,5′-dicarboxy-[1,1′-biphenyl]-3,4-dicarboxylato-K4O,O′:O″:O‴) cadmium(II)], C16H11O10Cd
  27. Crystal structure of {tetraaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)}-{triaqua-bis(1-(4-hydroxy-2-oxotetrahydrofuran-3-yl)-2-((4aS,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethane-1-sulfonato-k2O,O') calcium(II)} – water – acetone (1/1/8/2)
  28. Synthesis and crystal structure of bis{2-bromo-6-((E)-((4-((E)-1-(methoxy-imino)ethyl)phenyl)imino)methyl)phenolato- κ2N,O}zinc(II)-methanol(1/2), C65H60Br4N8O9Zn2
  29. Crystal structure of benzenesulphonic acid
  30. Crystal structure of N-benzyl-N-nicotinoyl-nicotine amide C19H15N3O2
  31. Crystal structure of poly[aqua(μ3-2,4-diamino-benzenesulfonato-κ4N:N′,O:O′)silver(I)], C12H18O8N4S2Ag2
  32. Crystal structure of 1,4-bis(methylpyridinium benzene) bis(1,2-dicyanoethene-1,2-dithiolato-κ2S:S)nickel(II), C26H18N6NiS4
  33. Crystal structure of the Cu(II) complex chlorido-(6-oxo-2-phenyl-1,6-dihydropyrimidine-4-carboxylato-k2N,O)-(phenanthroline-k2N,N')copper(II), C23H15ClCuN4O3
  34. Crystal structure of phenarsazine chloride acetic acid solvate, C14H13AsClNO2
  35. Crystal structure of poly[aqua-(μ2-3,3′,4,5′-biphenyl tetracarboxylate- κ3O,O′:O′′) -(μ2-4,4′-bis(pyrid-4-yl)biphenyl-κ2N:N′)zinc(II)], C27H18NO9Zn
  36. Crystal structure of catena-poly[(μ2-3-amino-benzenedisulfonato-κ2N:O)-bis (3-methyl-isoquinoline-κN)silver(I)], C26H24N3O3SAg
  37. Crystal structure of 2-((4-Aminophenyl)thio)acetic acid, C8H9NO2S
  38. Crystal structure of phenarsazine chloride dimethylsulfoxide solvate, C14H15AsClNOS
  39. Synthesis and crystal structure of 2-azido-N-phenylacetamide, C8H8N4O
  40. Crystal structure of chlorido{hydridotris[3-phenyl-5-methylpyrazol-1-yl-κN3]borato}copper(II), C30H28BClCuN6
  41. Crystal structure of benzanthrone – a redetermination for correct molecular geometry and localization of hydrogen atoms
  42. Crystal structure of 4-bromobenzaldehyde – complete redetermination at 200 K, C7H5BrO
  43. Crystal structure and spectroscopic properties of chlorido{hydridotris[3-,5-dimethylpyrazol-1-yl-κN3]borato}(3-,5-dimethylpyrazol-1-yl-κN)copper(II), C20H30BClCuN8
  44. The crystal structure of 4-((2-hydroxynaphthalen-1-yl)(pyrrolidin-1-yl)methyl)benzonitrile, C22H20N2O
  45. Crystal structure of 4-ethyl-3-phenylisoquinolin-1(2H)-one, C17H15NO
  46. Crystal structure of (tricyclohexylphosphane-κP)-[(Z)-N-(3-fluorophenyl)-O-methylthiocarbamato-k1S]gold(I), C26H40AuFNOPS
  47. Crystal structure of (3S,8R,10R,12R,14R)-12-hydroxy-4,4,8,10,14-pentamethyl-17-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl) hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate, C32H54O4
  48. The crystal structure of 2-[(S)-1-(naphthalen-1-yl)ethyl]-2,3,7,7a- tetrahydro-3a,6-epoxyisoindol-1(6H)-one, C19H20NO2
  49. Crystal structure of {hydridotris[3-(t-butyl)-5-isopropylpyrazol-1-yl-κN3]borato}thallium(I), C30H52BN6Tl
  50. Synthesis and crystal structure of 1-octyl-3-phenylquinoxalin-2(1H)-one, C22H26N2O
  51. The crystal structure of 2,6-difluorophenol, C6H4F2O
  52. 4-(9H-Fluoren-9-yl)-4-methylmorpholin-4-ium bromide, C18H20BrNO
  53. The crystal structure of 2,4-dimethylimidazole monohydrate, C5H10N2O
  54. The crystal structure of 1,2-dimethylimidazole, C5H8N2
  55. The crystal structure of 3-ammonio-4-aminobenzoate, C7H8N2O2 – a second polymorph
  56. The crystal structure of 4-hydroxy-2,5-bis(1-methyl-1H-imidazol-3-ium-2-ylthio)-3,6-dioxocyclohexa-1,4-dienolate chloride monohydrate, C14H15N4O5S2Cl
  57. The crystal structure of butyrylferrocene, C14H16FeO
  58. The crystal structure of bi-1,1′-cyclopentane-1,1′-diol, C10H18O2
  59. The crystal structure of 2-iso-propylimidazole, C6H10N2
  60. The crystal structure of aqua-tris (1,3-diphenylpropane-1,3-dionato-κ2O,O′)-lanthanum(III), C45H35LaO7
  61. Crystal structure of (3E,5E)-3,5-bis-4-methoxy-3-(trifluoromethyl)benzylidene)-1-methylpiperidin-4-one, C24H21F6NO3
  62. The crystal structure of 3,5-dichloro-6-diazo-2,4-dinitrocyclohexa-2,4-dien-1-one, C6Cl2N4O5
  63. Crystal structure of carbonyl(2-methylquinolin-8-olato-κ2N,O)(triphenylarsine-κAs)rhodium(I), C29H23AsNO2Rh
  64. Crystal structure of (1aS,1a1S,2S)-4a-butoxy-1a,1a1,2,4a,5,6-hexahydro-1H-cyclobuta[de]naphthalen-2-yl-4-nitrobenzoate, C22H25NO5
  65. Crystal structure of carbonyl(2-oxopyridin-1(2H)-olato-k2O,O′)(triphenylarsine-κAs)rhodium(I), C24H19AsNO3Rh
  66. Crystal structure of catena-poly[triqua-bis(μ2-4-carboxy-2-(1H-tetrazol-1-yl)-1H-imidazole-5-carboxylato-k3N,O:O′)barium(II)] tetrahydrate, C14H14BaN12O15
  67. Crystal structure of (E)-3′,6′-bis(ethylamino)-2-((quinoxalin-2-ylmethylene)amino)spiro[isoindoline-1,9′-xanthen]-3-one, C35H32N6O2
  68. Crystal structure of diaqua-bis(μ2-5-chloro-salicylato-κ3O,O′:O′)-bis(5-chloro-salicylato-κ2O,O′)-bis(1,10-phenanthroline-κ2N,N′) dilead(II) – water (1/2), C52H36C14N4O14Pb2·2(H2O)
  69. Crystal structure of (E)-2-(4-ethoxycarbonyl-3,5-dimethyl-2-(pyrrole-2-ylmethyleneamino)-3′,6′-dihydroxylspiro[isoindoline-1,9′-xanthen]-3-one-methanol (1/1), C31H29N3O7
  70. The crystal structure of 5H-dibenzo[b,e]azepine-6,11-dione, C14H9NO2
  71. Crystal structure of (E)-2-(4-fluoro-2-(trifluoromethyl)benzylidene)-7-methoxy-3,4-dihydronaphthalen-1(2H)-one, C19H14F4O2
  72. The crystal structure of N-(2-methoxy-4,5-bis[phenylselanyl]phenyl)picolinamide, C25H20N2O2Se2
  73. The crystal structure of (E)-2-(5-bromo-2-hydroxybenzylidene)-N-phenylhydrazine-1- carboxamide monohydrate, C14H14BrN3O3
  74. Crystal structure of fac-tricarbonyl-(nitrato-k1O)-bis(pyridine-κN)-rhenium, C13H10O6N3Re
  75. Crystal structure of (E)-2-(((1H-pyrrol-2-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one — methanol (1/2), C27H25N3O6
  76. The crystal structure of 4-amino-N′-(4-aminobenzoyl)benzohydrazide monohydrate, C14H16N4O3
  77. Crystal structure of bis(amino(carbamothioylamino)methaniminium) 5-hydroxyisophthalate monohydrate, C12H20N8O6S2
  78. The crystal structure of 2-(chloromethyl)pyridine, C6H6ClN
  79. The crystal structure of 1-bromo-4-iodo-benzene, C6H4BrI
  80. The crystal structure of 2,6-dimethyl-4-nitro-phenol, C8H9NO3
  81. The crystal structure of 3-chloropropionic acid, C3H5ClO2
  82. The crystal structure of 2-(2-methoxyphenyl)acetic acid, C9H10O3
Downloaded on 7.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2020-0422/html
Scroll to top button